Get started
Author

Nelson Cheinquer

Observed names: N CHEINQUER, N. Cheinquer
OpenAlex ID: A5033565780
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
2022 · Sunil S Solomon, Sandra Wagner-Cardoso, et al. · ˜The œLancet. Gastroenterology & hepatology · 111
Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis
2010 · Nelson Cheinquer, Hugo Cheinquer, et al. · The Brazilian Journal of Infectious Diseases · 18
PDF
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment
2022 · Mark Sulkowski, Laura E. Telep, et al. · Alimentary Pharmacology & Therapeutics · 15
PDF
290 - Long-Term Follow-Up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens
2018 · Andrew J. Muir, Alessandra Mangia, et al. · Gastroenterology · 11
Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients
2013 · Décio Passos Sampaio Péres, Hugo Cheinquer, et al. · Annals of Hepatology · 11
PDF
HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload
2002 · Silvia Coelho-Borges, Hugo Cheinquer, et al. · The American Journal of Gastroenterology · 9
Effect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin
2012 · Silvia Coelho-Borges, Hugo Cheinquer, et al. · Arquivos de Gastroenterologia · 5
PDF
Tu1502 – Ledipasvir/Sofosbuvir is Highly Effective and Safe in Patients with Chronic Hepatitis B Virus and Hepatitis C Virus Coinfection: Final Study Results
2019 · Chun-Jen Liu, Wan-Long Chuang, et al. · Gastroenterology · 3
PDF
Tu1501 – Ledipasvir/Sofosbuvir for 8, 12, Or 24 Weeks is Safe and Effective in Patients Undergoing Dialysis
2019 · Wan-Long Chuang, Tsung-Hui Hu, et al. · Gastroenterology · 2
953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis
2019 · Steven L. Flamm, Eric Lawitz, et al. · Gastroenterology · 2
PDF
Is sustained virologic response durable in patients with chronic hepatitis C treated with interferon alfa with or without ribavirin?
2002 · Nelson Cheinquer, Hugo Cheinquer, et al. · Journal of Hepatology · 2
S2246 Educational Needs in the Diagnosis and Management of Patients With Celiac Disease: A Practice Management Survey of Healthcare Professionals
2024 · Susan Cazzetta, Gregory Salinas, et al. · The American Journal of Gastroenterology · 1
A simple and safe approach to HCV treatment: Findings from the a5360 (MINMON) trial
2021 · Sunil S. Solomon, Sandra Wagner-Cardoso, et al. · Topics in antiviral medicine · 1
Tu1497 – Efficacy and Safety of Sofosbuvir/Velpatasvir for the Treatment of Patients with Chronic Hepatitis C Genotype 1-6 Infection: Integrated Analysis of Eight Phase 3 Clinical Trials
2019 · Eric Lawitz, Jordan J. Feld, et al. · Gastroenterology · 1
PDF
720 - Emergence and Long-Term Persistence of NS3, NS5A, and NS5B Resistance Associated Substitutions after Treatment with Direct-Acting Antivirals
2018 · David L. Wyles, Eric Lawitz, et al. · Gastroenterology · 1
291 - Long-Term Follow-Up of Patients with Chronic HCV and F2 or F3 Fibrosis after Achieving SVR with Daa-Based Therapy: Results from the Gilead SVR Registry
2018 · Ira M. Jacobson, Stefan Zeuzem, et al. · Gastroenterology · 1
Dilatacao endoscopica de esofago sem o auxilio de fluoroscopia: experiencia em 1358 sessoes
2002 · Julio C. Pereira Lima, Cláudio Augusto Marroni, et al. · GED. Gastrenterologia endoscopia digestiva · 1
Alfafetoproteína: valores normais no líquido amniótico entre 14 e 21 semanas
1998 · D. Maestri, M.T.V. Sanseverino, et al. · Revista da Associação Médica Brasileira · 1
PDF
Review Article: Accelerating Coeliac Disease Clinical Trials—Beyond Celiac Meeting With Industry, Academics, Patients and the FDA
2026 · Lisa M. Fahey, Robert Anderson, et al. · Alimentary Pharmacology & Therapeutics
Sa1255 SYMPTOM SEVERITY AND INADVERTENT GLUTEN EXPOSURE AMONG PATIENTS WITH CELIAC DISEASE
2026 · Mariel Arvizu, Jessica Marden, et al. · Gastrointestinal Endoscopy
Sa1255 SYMPTOM SEVERITY AND INADVERTENT GLUTEN EXPOSURE AMONG PATIENTS WITH CELIAC DISEASE
2026 · Mariel Arvizu, Jessica Marden, et al. · Gastroenterology
Tu1357: CHALLENGES AND OPPORTUNITIES IN THE MULTIDISCIPLINARY MANAGEMENT OF CELIAC DISEASE IN THE UNITED STATES: RESULTS OF A CASE-BASED SURVEY
2025 · Susan Cazzetta, Gregory Salinas, et al. · Gastroenterology
Tu1343: THE BURDEN OF CELIAC DISEASE BEFORE AND AFTER DIAGNOSIS IN TWO US HEALTH CLAIMS DATABASES
2025 · Fabiana Zingone, Mariel Arvizu, et al. · Gastroenterology
Tu1353: TEN-YEAR PREVALENCE OF DIAGNOSED CELIAC DISEASE IN THE UNITED STATES: A HEALTH CLAIMS DATABASE STUDY
2025 · Mariel Arvizu, Sudhakar Manne, et al. · Gastroenterology
717 - SOF/VEL/VOX for 12 Weeks is a Safe and Effective Salvage Regimen for NS5A Inhibitor-Experienced Patients with Genotype 1-6 HCV Infection: an Integrated Analysis of Phase 2 and Phase 3 Studies
2018 · Eric Lawitz, Michael Manns, et al. · Gastroenterology
Works count: 40
Citation count: 196
H-index: 6
I10-index: 5
Year
Topic
Type